Clinical Trials · NCT07282041
Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis
- Phase
- Phase 2/Phase 3
- Recruitment status
- Recruiting
- Sponsor
- National University of Singapore
- Enrollment
- 130
- Start date
- Dec 2025
- Locations
- 1 site, Singapore
- Primary endpoint
- To evaluate whether GLP1 RA (Dulaglutide) therapy would improveme cerebral vasodilatory reserve by at least 4 points in patients with severe stenosis of ICA or MCA